CJC-1295 DAC + Ipamorelin – Two Separate Research Peptide Vials

Product Overview

CJC-1295 DAC + Ipamorelin is a research peptide product supplied in two individual vials for laboratory research applications. The package contains one vial of CJC-1295 DAC and one vial of Ipamorelin. Each compound is provided separately rather than combined into a single blended vial.

This distinction is important when reviewing the product specifications, identifying individual batch numbers and examining the associated analytical test results. Both peptides are supplied as lyophilized powder in sealed, flip-top vials. The product is not reconstituted and is supplied in its original powder form.

Global Peptides Lab presents the product with key specification and testing information to help research professionals review the stated composition, reported purity, vial format and available quality-control results before making a purchasing decision.

Product Specifications

The following table summarizes the product information provided for this listing.

Specification	Details
Product name	CJC-1295 DAC + Ipamorelin
Number of vials	2 separate vials
CJC-1295 DAC	5 mg nominal quantity
Ipamorelin	10 mg nominal quantity
Container type	Sealed vial with flip-top cap
Vial size	3 mL per vial
Physical form	Lyophilized powder
Reconstitution status	Not reconstituted
Purity testing	Reported for both peptides
Endotoxin testing	LPS result reported as Pass
Intended application	Laboratory research only

The quantities above describe the product’s nominal specifications. The analytical results supplied with this listing also report measured values that differ from the nominal quantities. Refer to the testing section below for those results.

CJC-1295 DAC: Research Information

CJC-1295 DAC is a synthetic peptide studied for its interaction with growth hormone-releasing hormone (GHRH) pathways. The DAC designation refers to Drug Affinity Complex, a modification associated with binding to circulating albumin and an extended duration of exposure compared with unmodified GHRH-related peptides.

In scientific research, GHRH-related compounds are investigated to better understand biological signaling, receptor interactions and the regulation of growth hormone secretion. These mechanisms are complex, and research findings should not be interpreted as evidence that a product is safe, effective or suitable for personal use.

For researchers reviewing CJC-1295 DAC, product identity, batch traceability, analytical methods and the availability of appropriate supporting documentation are important considerations. The batch identifier supplied for this component is included in the quality information below.

Ipamorelin: Research Information

Ipamorelin is a synthetic peptide investigated for its activity at the growth hormone secretagogue receptor, commonly known as GHS-R1a. It differs from GHRH-related compounds in its receptor target and mechanism of action.

Scientific investigations involving Ipamorelin examine receptor signaling and related physiological pathways. Its research profile is distinct from that of CJC-1295 DAC, which is why the two compounds should be identified separately in product documentation.

For laboratory research, accurate compound identification and traceable batch records help distinguish one material from another. The reported purity result and batch identifier provided for the Ipamorelin vial are listed in the testing section of this page.

The presence of two different peptides in one package does not mean they have been premixed. This listing represents two individually sealed vials, each with its own product identity and batch information.

Laboratory Testing and Reported Results

Product quality information is an important part of evaluating research materials. The results supplied for this listing include reported purity, measured sample quantity and an endotoxin (LPS) screening outcome.

CJC-1295 DAC test results

• Reported purity: 96.135%
• Reported measured quantity: 5.64 mg
• Batch number: 08-25-0705H

Ipamorelin test results

• Reported purity: 99.776%
• Reported measured quantity: 11.98 mg
• Batch number: 08-25-0710G

Endotoxin testing

• Test: Endotoxin (LPS)
• Reported result: Pass

These figures are the results provided for the product and should be checked against the corresponding laboratory documentation. A reported purity percentage describes the result under the analytical method used; it does not, by itself, establish every aspect of a material’s quality, identity, sterility or suitability for a particular research application.

Likewise, an endotoxin test reported as Pass should be interpreted in the context of the laboratory’s method, acceptance criteria and reporting limit. It should not automatically be treated as proof of sterility or as evidence that a product is suitable for injection or human use.

Customers conducting laboratory research should review the applicable certificate of analysis (COA), including the laboratory identity, testing date, methods and acceptance criteria, where available.

Packaging and Physical Form

Both compounds are supplied as lyophilized powder in separate, sealed vials with flip-top caps. Each vial has a stated container size of 3 mL.

Lyophilization is a freeze-drying process used to remove water from a material under controlled conditions. It is commonly used in the preparation of laboratory materials that require a dry physical format. However, the presence of lyophilized powder alone does not establish a particular shelf life or storage requirement.

The product is supplied not reconstituted. No reconstitution procedure, administration instructions or human-use dosing recommendations are provided as part of this product description.

Before using a research material in an approved laboratory protocol, researchers should consult the relevant documentation for handling requirements, compatibility, storage conditions and any applicable safety precautions.

What Is Included in the Package?

The package contains two separate items:

1. One CJC-1295 DAC vial, with a nominal quantity of 5 mg.
2. One Ipamorelin vial, with a nominal quantity of 10 mg.

Each vial is separately sealed and identified by its corresponding peptide and batch information. This format makes it easier to distinguish the two materials when reviewing inventory records and laboratory documentation.

Please note that this is not one vial containing a premixed combination. The two compounds have separate reported purity results and separate batch identifiers.

Storage and Handling Considerations

Follow the storage and handling instructions provided in the applicable product documentation and certificate of analysis. Do not assume that all lyophilized peptides have identical temperature, light-protection or shelf-life requirements.

Keep research materials in their original, appropriately labeled containers and maintain clear batch records. Access should be restricted to trained personnel working under applicable laboratory safety procedures.

Do not use a product if its packaging is compromised, its identity cannot be established or the available documentation raises unresolved quality concerns. Disposal should follow the laboratory’s applicable chemical and biological waste procedures.

Frequently Asked Questions

Is CJC-1295 DAC + Ipamorelin supplied in one vial?

No. The package contains two separate vials: one CJC-1295 DAC vial and one Ipamorelin vial. They are not supplied as a single blended vial.

What quantities are listed for the two peptides?

The nominal product quantities are 5 mg for CJC-1295 DAC and 10 mg for Ipamorelin. The supplied test information separately reports measured quantities of 5.64 mg and 11.98 mg, respectively.

What are the reported purity results?

The supplied results report 96.135% purity for CJC-1295 DAC and 99.776% purity for Ipamorelin. Consult the corresponding analytical documentation for the methods and reporting details.

Has the product been tested for endotoxins?

The supplied product information reports an endotoxin (LPS) result of Pass. The test method, acceptance limit and scope should be confirmed from the applicable laboratory report.

Is the product supplied as a liquid?

No. Both components are described as lyophilized powder in sealed vials. The product is not reconstituted.

What are the batch numbers?

The listed CJC-1295 DAC batch is 08-25-0705H. The listed Ipamorelin batch is 08-25-0710G.

Is this product intended for human use?

No. This listing is intended for laboratory research purposes only. It is not offered for human or veterinary administration, and the product description does not establish safety or effectiveness for clinical use.

Final Product Summary

CJC-1295 DAC + Ipamorelin is a two-vial research peptide package featuring separately sealed CJC-1295 DAC and Ipamorelin lyophilized powders. The listing identifies the nominal quantities, vial format, individual batch numbers, reported purity measurements and the supplied endotoxin screening result.

Global Peptides Lab aims to present product specifications clearly so qualified research customers can review the available information before purchasing. For a complete assessment of product quality, consult the relevant batch documentation and laboratory reports rather than relying on a product listing alone.

Research-use notice: For laboratory research only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease.